title: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
abstract: OBJECTIVE
  This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease.
  
  
  METHODS
  Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m2 on days 1, 22, and 43, followed by cisplatin 80 mg/m2 and fluorouracil 1,000 mg/m2/d for 96 hours starting on days 71, 99, and 127.
  
  
  RESULTS
  From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024).
  
  
  CONCLUSIONS
  Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio.
authors.affiliation: Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China. awmlee@ha.org.hk
authors.forename: Anne W M
authors.initials: AW
authors.lastname: Lee
authors.forename: W H
authors.initials: WH
authors.lastname: Lau
authors.forename: Stewart Y
authors.initials: SY
authors.lastname: Tung
authors.forename: Daniel T T
authors.initials: DT
authors.lastname: Chua
authors.forename: Rick
authors.initials: R
authors.lastname: Chappell
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: Lillian
authors.initials: L
authors.lastname: Siu
authors.forename: W M
authors.initials: WM
authors.lastname: Sze
authors.forename: T W
authors.initials: TW
authors.lastname: Leung
authors.forename: Jonathan S T
authors.initials: JS
authors.lastname: Sham
authors.forename: Roger K C
authors.initials: RK
authors.lastname: Ngan
authors.forename: Stephen C K
authors.initials: SC
authors.lastname: Law
authors.forename: T K
authors.initials: TK
authors.lastname: Yau
authors.forename: Joseph S K
authors.initials: JS
authors.lastname: Au
authors.forename: Brian
authors.initials: B
authors.lastname: O'Sullivan
authors.forename: Ellie S Y
authors.initials: ES
authors.lastname: Pang
authors.forename: S K
authors.initials: SK
authors.lastname: O
authors.forename: Gordon K H
authors.initials: GK
authors.lastname: Au
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Lau
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil